Accelerating the Clinical Translation of Selective RNA-Targeting Small Molecules

Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com

Optimizing RNA-Targeting Small Molecules Through Structure-Guided Design, Selective Modulation, and Translational Strategies to Develop Safe, Bioavailable, and Clinically Effective Therapies

RNA-targeting small molecules were rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offered a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field saw major collaborations, including Wayfinder Biosciences with Daiichi SankyoOno Pharmaceutical with Reborna Biosciences, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence.

In its 8th year, the RNA-Targeted Drug Discovery & Development Summit returned as the only dedicated industry forum addressing the unique challenges of RNA-targeted drug development across splice modulators, covalent drugs, proximity inducers and direct RNA binders.

Attendees joined 25+ world-class speakers from leaders like PTC TherapeuticsReviR TherapeuticsRemix TherapeuticsRgenta TherapeuticsArrakis Therapeutics and more in December where they gained the connections, tools and scientific firepower needed to bring their RNA-targeted therapeutics to clinic and beyond.

The 8th RNA-Targeted Drug Discovery & Development Summit offers a unique opportunity to engage with leading experts and innovators who are driving progress in this rapidly evolving field. As RNA-targeted therapeutics advance, the summit serves as a vital platform to exchange cutting-edge insights, foster collaboration across academia and industry, and accelerate breakthroughs. I look forward to contributing to the dialogue and helping to advance the next generation of RNA-targeted drugs.

Ella Czarina Morishita, Chief Scientific Officer, Veritas In Silico

Veritas In Silico

The RNA-Targeted Drug Discovery & Development Summit has evolved into a valuable touchbase for scientists spanning diverse areas of drug discovery and biotech. It serves as a forum for connection and discussion, as the field aggressively pursues novel therapies for diseases of unmet medical need.

Christopher Trotta, Senior Vice President Discovery Biology, PTC Therapeutics

PTC Therapeutics

2025 Full Event Guide

  • 22+ Expert Speakers
  • 3 Days of RNA-Targeted Content
  • 2 Interactive Workshops on Functional Binder Discovery
  • Investments & Deals Panel
8th RNA-Targeted Drug Discovery Summit Brochure

Attending as a team. Leaving with a strategy.

Untitled-design-80x80
Aligning Strategy Across RNA Drug Discovery

Attendees united cross-functional teams around shared challenges—from early target validation and RNA structure elucidation to novel binder chemistry—for a more integrated approach to RNA-targeted drug development.

Untitled-design-80x80
Tackling Cross-Departmental Challenges in One Place

The Summit brought together Directors and Scientists from discovery biology, chemistry, structural biology, pharmacology, and more to break down organizational silos and address interconnected pain points across strategy and technical teams.

Untitled-design-80x80
Benchmarking Against Industry Innovators

Learning directly from senior leaders at companies like PTC Therapeutics, Remix Therapeutics, Revir Therapeutics and more, attendees saw what was working across the most complex RNA-targeted programs — then adapted those strategies for their own pipeline.

Untitled-design-80x80
Empowering Your Team with Pharma & VC Insights

From insights on investment trends and recent deals to what large pharma and VCs were looking for in a biotech, attendees equipped their teams with practical tactics to attract collaborators and funding to accelerate RNA drug discovery and development.

Untitled-design-80x80
Maximizing Value with Group Savings

Attendees secured up to 20% off their passes with team discounts — and ensured their entire team walked away aligned, inspired, and ready to deliver on their RNA-targeted drug discovery goals.

What You Missed

80+

Attendees

25+

World-Class Speakers

18+

Data-Led Presentations

 

10+

Hours of Dedicated Networking

8

Hours of Interactive Workshops & Panels

1

Global RNA-Targeted Community

Official Partners

8th RNA-Targeted Drug Discovery Summit Brochure
Quick Download
Speakers Image
Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.

Networking Image (2) (1) (1) (1)
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

4-1 (1)
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.